Merck Total Liabilities 2010-2023 | MRK

Merck total liabilities from 2010 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Merck total liabilities for the quarter ending December 31, 2023 were $69.040B, a 9.41% increase year-over-year.
  • Merck total liabilities for 2023 were $69.04B, a 9.41% increase from 2022.
  • Merck total liabilities for 2022 were $63.102B, a 6.43% decline from 2021.
  • Merck total liabilities for 2021 were $67.437B, a 1.89% increase from 2020.
Merck Annual Total Liabilities
(Millions of US $)
2023 $69,040
2022 $63,102
2021 $67,437
2020 $66,184
2019 $58,396
2018 $55,755
2017 $53,303
2016 $55,069
2015 $56,910
2014 $49,376
2013 $53,319
2012 $50,669
2011 $48,185
2010 $48,976
2009 $50,829
Merck Quarterly Total Liabilities
(Millions of US $)
2023-12-31 $69,040
2023-09-30 $65,427
2023-06-30 $65,727
2023-03-31 $60,891
2022-12-31 $63,102
2022-09-30 $62,557
2022-06-30 $63,777
2022-03-31 $65,715
2021-12-31 $67,437
2021-09-30 $57,631
2021-06-30 $57,300
2021-03-31 $63,808
2020-12-31 $66,184
2020-09-30 $60,530
2020-06-30 $62,871
2020-03-31 $58,613
2019-12-31 $58,396
2019-09-30 $56,406
2019-06-30 $56,228
2019-03-31 $54,684
2018-12-31 $55,755
2018-09-30 $52,474
2018-06-30 $52,274
2018-03-31 $52,140
2017-12-31 $53,303
2017-09-30 $53,177
2017-06-30 $53,092
2017-03-31 $56,473
2016-12-31 $55,069
2016-09-30 $54,378
2016-06-30 $53,029
2016-03-31 $54,854
2015-12-31 $56,910
2015-09-30 $55,553
2015-06-30 $55,944
2015-03-31 $60,428
2014-12-31 $49,376
2014-09-30 $56,448
2014-06-30 $49,344
2014-03-31 $55,896
2013-12-31 $53,319
2013-09-30 $56,413
2013-06-30 $56,771
2013-03-31 $50,594
2012-12-31 $50,669
2012-09-30 $48,089
2012-06-30 $47,852
2012-03-31 $48,195
2011-12-31 $48,185
2011-09-30 $48,938
2011-06-30 $48,273
2011-03-31 $49,026
2010-12-31 $48,976
2010-09-30 $49,792
2010-06-30 $48,505
2010-03-31 $51,251
2009-12-31 $50,829
2009-09-30 $23,390
2009-06-30 $26,670
2009-03-31 $24,542
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $321.391B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
AbbVie (ABBV) United States $300.196B 15.26
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Sanofi (SNY) $120.637B 10.86
Innoviva (INVA) United States $0.959B 6.77